Arteris (AIP) counsel exercises 4,000 options, sells stock under 10b5-1 plan

Q: What insider activity did Arteris (AIP) executive Paul L. Alpern report?

Paul L. Alpern, Arteris’s VP and General Counsel , reported exercising 4,000 stock options at $0.56 per share and receiving 4,000 common shares. He then sold 600 and 3,400 shares in two separate transactions on August 3, 2026.

Q: How many Arteris (AIP) stock options did Paul L. Alpern exercise and at what price?

He exercised 4,000 incentive stock options for Arteris common stock at an exercise price of $0.56 per share . These options were part of a grant that began vesting in 2020, with 25% vesting initially and the remainder vesting monthly over three years.

Q: At what prices did Paul L. Alpern sell Arteris (AIP) common shares?

Alpern sold 600 shares at a weighted-average price of $29.11 and 3,400 shares at a weighted-average price of $30.1991 . The sales occurred in multiple trades within price ranges of $28.76–$29.54 and $29.76–$30.54 , respectively.

Q: How many Arteris (AIP) options remain from the reported grant after these transactions?

After exercising 4,000 options, Alpern continued to hold 53,000 incentive stock options from this grant. These options are scheduled to expire on October 23, 2029 , and had vested over time based on a defined vesting schedule starting in 2020.

Q: What is the vesting schedule for the Arteris (AIP) incentive stock option reported?

The reported incentive stock option vested 25% of the total shares on August 26, 2020 . Thereafter, 1/48th of the total shares vested monthly for three years, beginning on September 26, 2020 , leading to full vesting over the multi-year period.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Arteris, Inc. VP and General Counsel Paul L. Alpern exercised 4,000 incentive stock options at $0.56 per share on August 3, 2026, receiving 4,000 shares of common stock. The same day, he sold 600 and 3,400 shares at weighted-average prices of $29.11 and $30.1991 in transactions made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. Following the option exercise, 53,000 options from this grant remained outstanding.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,000 shares ($118K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Alpern Paul L

Role VP and General Counsel

Sold 4,000 shs ($120K)

Approx. gross sale proceeds $120K

Approx. exercise cost $2K

Approx. pre-tax spread $118K

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (right to buy) ^F4	4,000	$0.00	$0.00
Exercise	Common Stock ^F1	4,000	$0.56	$2K
Sale	Common Stock ^{F1, F2}	600	$29.11	$17K
Sale	Common Stock ^{F1, F3}	3,400	$30.1991	$103K

Holdings After Transaction: Incentive Stock Option (right to buy) — 53,000 shares (Direct); Common Stock — 70,733 shares (Direct)

Footnotes (4)

F1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on February 23, 2026.
F2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.76 to $29.54 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.76 to $30.54 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. Incentive stock option, 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26, 2020.

Key Figures

Options exercised: 4,000 shares Option exercise price: $0.56 per share Shares sold (first block): 600 shares +4 more

7 metrics

Options exercised 4,000 shares Incentive Stock Options exercised on 2026-08-03

Option exercise price $0.56 per share Exercise price for Incentive Stock Options converted into common stock

Shares sold (first block) 600 shares Common Stock sold at weighted-average price of $29.11 on 2026-08-03

Weighted-average sale price (first block) $29.11 per share Sales executed within a $28.76–$29.54 price range

Shares sold (second block) 3,400 shares Common Stock sold at weighted-average price of $30.1991 on 2026-08-03

Weighted-average sale price (second block) $30.1991 per share Sales executed within a $29.76–$30.54 price range

Remaining options from grant 53,000 options Incentive Stock Options remaining after exercise, expiring 2029-10-23

Key Terms

Incentive Stock Option, Rule 10b5-1 trading plan, weighted average sale price, vested monthly

4 terms

Incentive Stock Option financial

""Incentive Stock Option (right to buy)" describes the derivative security."

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan that was adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported in Column 4 is a weighted average sale price."

vested monthly financial

"Thereafter, 1/48th of the total shares vested monthly for 3 years..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 06:05 PM Accepted by SEC EDGAR 08/05/2026 - 06:05 PM

FAQ

What insider activity did Arteris (AIP) executive Paul L. Alpern report?

Paul L. Alpern, Arteris’s VP and General Counsel, reported exercising 4,000 stock options at $0.56 per share and receiving 4,000 common shares. He then sold 600 and 3,400 shares in two separate transactions on August 3, 2026.

How many Arteris (AIP) stock options did Paul L. Alpern exercise and at what price?

He exercised 4,000 incentive stock options for Arteris common stock at an exercise price of $0.56 per share. These options were part of a grant that began vesting in 2020, with 25% vesting initially and the remainder vesting monthly over three years.

At what prices did Paul L. Alpern sell Arteris (AIP) common shares?

Alpern sold 600 shares at a weighted-average price of $29.11 and 3,400 shares at a weighted-average price of $30.1991. The sales occurred in multiple trades within price ranges of $28.76–$29.54 and $29.76–$30.54, respectively.

Were Paul L. Alpern’s Arteris (AIP) trades made under a Rule 10b5-1 plan?

Yes. The reported stock transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Paul L. Alpern on February 23, 2026. Rule 10b5-1 plans pre-arrange trading activity according to preset instructions, independent of subsequent market developments.

How many Arteris (AIP) options remain from the reported grant after these transactions?

After exercising 4,000 options, Alpern continued to hold 53,000 incentive stock options from this grant. These options are scheduled to expire on October 23, 2029, and had vested over time based on a defined vesting schedule starting in 2020.

What is the vesting schedule for the Arteris (AIP) incentive stock option reported?

The reported incentive stock option vested 25% of the total shares on August 26, 2020. Thereafter, 1/48th of the total shares vested monthly for three years, beginning on September 26, 2020, leading to full vesting over the multi-year period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alpern Paul L

(Last)

(First)

(Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL

CALIFORNIA

95008

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	VP and General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/03/2026		M⁽¹⁾		4,000	A	$0.56	74,733	D
Common Stock	08/03/2026		S⁽¹⁾		600	D	$29.11⁽²⁾	74,133	D
Common Stock	08/03/2026		S⁽¹⁾		3,400	D	$30.1991⁽³⁾	70,733	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Incentive Stock Option (right to buy)	$0.56	08/03/2026		M			4,000	⁽⁴⁾	10/23/2029	Common Stock	4,000	$0.00	53,000	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on February 23, 2026.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $28.76 to $29.54 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.76 to $30.54 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. Incentive stock option, 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26, 2020.

Remarks:

	/s/ Paul Alpern	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR